ProMIS Neurosciences is trading 5.28% up now at $13.76, reversing the 5.19% decline on August 31; no direct catalyst has been identified for the September 1 gain.
- The company announced September conference appearances and investor meetings covering PMN310 and the PRECISE-AD Alzheimer’s trial.
- No new clinical, financial, regulatory, or partnership catalyst directly explains the move.
- The broader biotech sector and major indexes are lower.